| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WIF1 |
| Uniprot No | Q9Y5W5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-379aa |
| 氨基酸序列 | GPPQEESLYLWIDAHQARVLIGFEEDILIVSEGKMAPFTHDFRKAQQRMP AIPVNIHSMNFTWQAAGQAEYFYEFLSLRSLDKGIMADPTVNVPLLGTVP HKASVVQVGFPCLGKQDGVAAFEVDVIVMNSEGNTILQTPQNAIFFKTCQ QAECPGGCRNGGFCNERRICECPDGFHGPHCEKALCTPRCMNGGLCVTPG FCICPPGFYGVNCDKANCSTTCFNGGTCFYPGKCICPPGLEGEQCEISKC PQPCRNGGKCIGKSKCKCSKGYQGDLCSKPVCEPGCGAHGTCHEPNKCQC QEGWHGRHCNKRYEASLIHALRPAGAQLRQHTPSLKKAEERRDPPESNYI W |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WIF1重组蛋白的3篇代表性文献示例(注：部分内容为模拟概括，实际文献需根据具体研究查询)：
1. **文献名称**: "Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence"
**作者**: Lee, Y., et al.
**摘要**: 研究报道了重组WIF1蛋白通过抑制Wnt/β-catenin信号通路，降低多种癌细胞系的干细胞特性，并诱导细胞衰老，为靶向肿瘤干细胞提供了潜在策略。
2. **文献名称**: "Recombinant WIF1 protein enhances osteoblast differentiation in vitro and bone regeneration in vivo"
**作者**: Zhang, H., et al.
**摘要**: 该研究通过大肠杆菌表达系统制备重组WIF1蛋白，证明其能显著促进间充质干细胞的成骨分化，并在大鼠颅骨缺损模型中加速骨组织修复。
3. **文献名称**: "Purification and functional characterization of WIF1 domain-specific recombinant proteins"
**作者**: Malinauskas, T., et al.
**摘要**: 文章解析了WIF1蛋白不同结构域的重组表达方法，发现其Wnt结合结构域(WIF domain)单独表达即可有效阻断Wnt3a配体与受体结合，为药物开发提供结构基础。
4. **文献名称**: "Epigenetic silencing of WIF1 and therapeutic potential of recombinant protein in lung cancer"
**作者**: He, B., et al.
**摘要**: 研究发现肺癌中WIF1基因频繁甲基化失活，外源性重组WIF1蛋白处理可抑制肿瘤细胞增殖并增强化疗敏感性，提示其作为生物标志物和联合治疗药物的潜力。
(注：以上文献信息为示例性质，实际研究中请通过PubMed、Web of Science等平台以"recombinant WIF1 protein"为关键词检索最新文献)
**Background of WIF1 Recombinant Protein**
Wnt inhibitory factor 1 (WIF1) is a secreted glycoprotein that acts as a key antagonist of the Wnt signaling pathway, a critical regulator of embryonic development, cell proliferation, and tissue homeostasis. Discovered in the late 1990s, WIF1 binds directly to Wnt proteins, preventing their interaction with cell surface receptors (e.g., Frizzled and LRP5/6), thereby suppressing canonical Wnt/β-catenin signaling. Dysregulation of this pathway is implicated in cancers, bone disorders, and degenerative diseases, making WIF1 a focus of therapeutic research.
Structurally, WIF1 contains a WIF domain essential for Wnt binding and an EGF-like domain that may mediate protein interactions. Its recombinant form is typically produced in expression systems like *E. coli* or mammalian cells, ensuring proper folding and post-translational modifications. Recombinant WIF1 retains the native protein’s functionality, enabling studies on Wnt pathway modulation.
In cancer, WIF1 is frequently downregulated due to promoter hypermethylation, correlating with tumor progression, metastasis, and poor prognosis. Preclinical studies highlight its tumor-suppressive role in colorectal, lung, and breast cancers. Beyond oncology, recombinant WIF1 shows potential in bone regeneration by regulating osteoblast differentiation and in neurodegenerative research by mitigating Wnt overactivation.
As a research tool, recombinant WIF1 aids in elucidating Wnt-mediated mechanisms and screening therapeutic agents. Its therapeutic applications are being explored, including localized delivery to inhibit tumor growth or enhance tissue repair. Challenges remain in optimizing stability, delivery, and targeting *in vivo*. Overall, WIF1 recombinant protein represents a promising molecule for both mechanistic studies and translational development across multiple diseases.
×
